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Background: It remains unclear how closely the physical inactivity observed in patients with
Chronic Obstructive Pulmonary Disease (COPD) relates to the severity of their airflow limita-
tion. Furthermore, it is unknown whether spirometric variables such as maximal voluntary ven-
tilation (MVV) and inspiratory capacity (IC) reflect the level of physical activity in daily life
better than the forced expiratory volume in the first second (FEV1), the main spirometric vari-
able used to determine the severity of COPD. The objective of the present study was to inves-
tigate the relationship between physical activity in daily life and the severity of COPD assessed
by different spirometric variables: MVV, IC and FEV1.
Methods: Forty patients with COPD (21 men; 68  7 years; FEV1 41  14% predicted) were
performed spirometry and assessment of the physical activity level in daily life using an
accelerometer (SenseWear Armband).
Results: MVV was significantly correlated to total energy expenditure per day, energy expen-
diture per day in activities demanding more than 3 metabolic equivalents (METs), number of
steps per day and time spent per day in moderate and vigorous activities (0.42 r 0.52;
p< 0.01 for all). Correlation of these variables with IC and especially FEV1 was more modest,
borderline or not statistically significant. There was no difference in time spent in vigorous
activities among patients classified according to the FEV1-based GOLD stages II, III and IV,to de Fisioterapia, CCS, Universidade Estadual de Londrina, Hospital Universita´rio Regional Norte do
ra´ria, 86038-440 Londrina, Parana´, Brazil. Tel.: þ55 43 33712288; fax: þ55 43 33712459.
om.br, fabio.pitta@hotmail.com (F. Pitta).
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1204 F. Pitta et al.differently than that observed when patients were classified in groups according to
their MVV.
Conclusion: In COPD patients, MVV better reflects the physical activity level in daily life
than FEV1 and IC.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
A reduction in the forced expiratory volume in the first
second (FEV1) is the most common outcome used to gradu-
ate the severity of Chronic Obstructive Pulmonary Disease
(COPD).1 However, literature is controversial concerning
whether the reduction in the level of physical activity
observed in patients with COPD is directly linked to the
degree of airflow limitation severity or whether other
factors interfere, leading inactivity to occur independently
of the airflow limitation severity as measured by the FEV1.
Furthermore, it is unknown whether other spirometric vari-
ables such as maximal voluntary ventilation (MVV) and in-
spiratory capacity (IC) are more closely linked than the
FEV1 to the level of physical activity in daily life as well as
to important outcomes in COPD such as functional exercise
capacity and respiratory muscle force. The main objective
of the present study was to investigate the relationship
between physical activity in daily life and spirometric impair-
ment assessed by different variables (FEV1, MVV and IC) in
patients with COPD. A secondary objective was to investigate
the relationship of these 3 spirometric variables with func-
tional exercise capacity and respiratory muscle force.
Methods
Forty consecutive patients in screening process for admis-
sion in a pulmonary rehabilitation program were included.
Data were collected from June 2006 until June 2007.
Admission of patients to the study was done throughout
the whole year to avoid seasonal bias in the assessment of
physical activity in daily life. The diagnosis of COPD was
established based on internationally accepted criteria.1
Inclusion criteria were: clinical stability (absence of exac-
erbations) for at least 3 months before inclusion in the
study; and absence of osteo-neuro-muscular co-morbidities
that might interfere in the assessments. Patients would be
excluded if not able to finalize the proposed assessments by
physical or cognitive reasons or if not willing to continue in
the study for any reason. The study was approved by the
institution’s Committee for Ethics in Research, and all
patients gave formal written consent to participate.
Spirometric assessment was performed using the Pony
Cosmed spirometer (Cosmed, Italy) according to the
guidelines of the ATS/ERS.2 Concerning the MVV testing,
after 3 breaths at tidal volume, the patient performed
the manoeuvre breathing as deeply and rapidly as possible
for 12 s. The technician enthusiastically coached the
subjects throughout the test, and suggested faster or
slower breathing if necessary to achieve an ideal rate of
90e110 breaths/min in order to obtain an acceptable ma-
noeuvre. Three valid and reproducible manoeuvres were
obtained, and the best was used for the analysis. Relativerelationship of MVV with the FEV1 (MVV/(FEV1 40)) was
0.94, demonstrating that the MVV manoeuvre was properly
performed and did not lack appropriate effort from the
patients.2 IC was obtained through the formula: VCERV
(‘‘slow’’ vital capacityexpiratory reserve volume). All
values used for analysis were obtained after bronchodila-
tion. Reference values were those from Knudson et al.3
Maximal inspiratory pressure (MIP) and maximal expira-
tory pressure (MEP) assessments were performed with an
analogic manovacuometer Gerar (Gerar, Brazil) according
to the technique described by Black and Hyatt,4 with refer-
ence values from Neder et al.5 The 6-min walking test
(6MWT) was performed according to the guidelines of the
American Thoracic Society.6 Reference values were those
from Troosters et al.7
Physical activity in daily life was assessed by the Sense-
Wear Armband (Bodymedia, United States), a physiologic
activity monitor which records continuous data about
energy expenditure and physical activity habits in subjects
during their daily life. The device is light, portable, worn
in the upper posterior part of the arm and was previously
validated in patients with COPD.8 Assessment was per-
formed for 2 days, during 12 h per day (from the moment
the patient wakes up until 12 h after that), and the average
of the 2 days was used for analysis. Results were obtained
through the analysis of the data by the specific software pro-
vided by Bodymedia (InnerView, Bodymedia, United States).
Statistical analysis was performed with the software
GraphPad Prism 3.01. Distribution of the data was assessed
using the KolmogoroveSmirnov test. Since the variables
from the physical activity assessment were non-normally
distributed, correlations were performed using the Spear-
man correlation coefficient. Comparison among the groups
classified according to the values of FEV1 and MVV was
performed using KruskaleWallis test, with the Dunn’s post-
test when applicable. The level of significance was
determined as p< 0.05.
Results
No patient refused to perform the assessments or was not
capable of performing them, and therefore no patient was
excluded from the study. The general characteristics of the
group of patients included in the study are shown in Table 1
(nZ 40; 21 male; 1 patient GOLD stage I, 11 GOLD II, 19
GOLD III, 9 GOLD IV). In this group of patients, BMI was
not significantly correlated to FEV1 (rZ 0.19; pZ 0.25)
and IC (rZ 0.11; pZ 0.51), whereas its correlation with
MVV tended to be slightly higher, although not reaching
statistical significance (rZ 0.29; pZ 0.09).
Table 2 shows that there were significant correlations
between MVV, IC and FEV1 in one hand and MIP and MEP
in the other (p< 0.05 for all). In general, MVV had higher
Table 1 General characteristics of the group of patients
with COPD included in the study (nZ 40, except when
otherwise indicated)
Mean (SD)
Age (years) 68 (7)
BMI (kg/m2) 24 (6)
FVC (% pred) 66 (19)
FEV1 (l) 0.90 (0.26)
FEV1 (% pred) 41 (14)
MVV (l) (nZ 39) 34 (13)
MVV (% pred) (nZ 39) 37 (15)
IC (l) 1.44 (0.52)
MIP (% pred) (nZ 30) 71 (29)
MEP (% pred) (nZ 30) 111 (34)
6MWT (%pred) 75 (17)
TEE (kcal/day) 1235 (547)
EEA> 3 METs (kcal/day) 412 (499)
Steps/day 4178 (3007)
TSA> 3 METs (min/day) 79 (72)
Results are shown as mean (standard deviation). COPDZChronic
Obstructive Pulmonary Disease; BMIZbody mass index;
FVCZ forced vital capacity; FEV1Z forced expiratory volume in
the first second; MVVZmaximal voluntary ventilation; ICZ inspir-
atory capacity; TEEZ total energy expenditure per day; EEA> 3
METsZ energy expenditure per day in physical activities demanding
more than 3 metabolic equivalents; steps/dayZ number of steps
per day; TSA> 3METsZ time spent per day in activities with energy
expenditure above 3 metabolic equivalents; MIPZmaximal inspira-
tory pressure; MEPZmaximal expiratory pressure; 6MWTZ 6-min
walking test.
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Pulmonary function and daily physical activity in COPD 1205correlations with MIP and MEP than IC and FEV1. MVV and IC
also showed significant correlation with the 6MWT (rZ 0.50
and 0.51, respectively; p< 0.005 for both), whereas the
same was not observed for the correlation between FEV1
and 6MWT (rZ 0.29; pZ 0.07).
Table 2 also shows that MVV was significantly correlated
with all variables concerning physical activity in daily life
(0.42 r 0.52; p< 0.01 for all). Correlations of these
same variables with IC and especially FEV1 were more mod-
est, borderline or not statistically significant (Table 2). If
total energy expenditure per day and energy expenditure
per day in physical activities demanding more than 3 meta-
bolic equivalents (METs) were corrected for body weight,
the results were rigorously maintained, with MVV showing
better correlation with these variables in comparison to
IC and especially to FEV1.
Fig. 1 shows the comparison of time spent per day in vig-
orous activities (demanding 6e9 METs) among patients classi-
fied in 3 subgroups according to the FEV1 (corresponding to
GOLD stages II, III and IV; (A)) and according to the MVV in
similar intervals as used for the FEV1 (i.e., 50e80% predicted,
30e49% predicted, and 29% predicted; (B)). Fig. 1A shows
no significant difference among the groups classified by
GOLD stages (pZ 0.65). Furthermore, there was no correla-
tion between the GOLD stages with any variable from physi-
cal activity in daily life, maximal respiratory pressures and
6MWT (0.25< r< 0.16; p> 0.05 for all). Fig. 1B shows sta-
tistically significant difference when comparing the subgroup
MVV 29% predicted with the other 2 subgroups (pZ 0.02;
Dunn’s post-test p< 0.05 for both analyses).
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Figure 1 Comparison of time spent per day in vigorous activities (demanding 6e9 metabolic equivalents e METs) among patients
classified according to: (A) forced expiratory volume in the first second (FEV1) in 3 subgroups: left column (white): 50% FEV1< 80%
predicted e GOLD II (nZ 11); middle column (grey): 30% FEV1 49% predicted e GOLD III (nZ 19); right column (black):
FEV1 29% predicted e GOLD IV (nZ 9); (B) maximal voluntary ventilation (MVV) in 3 subgroups: left column (white):
50%MVV< 80% predicted (nZ 8); middle column (grey): 30%MVV 49% predicted (nZ 16); right column (black): MVV 29%
predicted (nZ 15). Predicted values according to Knudson et al. GOLDZ global initiative for obstructive lung disease. In (A)
nZ 39 since 1 patient was classified as GOLD I. Analysis performed with the KruskaleWallis test showed no statistically significant
difference among the groups (pZ 0.65). In (B) nZ 39 since MVV was not obtained in 1 patient. Analysis performed with the Krus-
kaleWallis test showed pZ 0.02 (*p< 0.05 in the Dunn’s post-test).
1206 F. Pitta et al.Discussion
The present study showed that, in patients with COPD, MVV is
better correlated to different outcomes from physical activ-
ity in daily life than FEV1 and IC. MVV, IC and FEV1, although
known to be correlated, are spirometric variables which
reflect the different aspects of lung function. While FEV1
reflects basically the airflow limitation, MVV additionally
reflects the ventilatory reserve available to respond to the
increased physiologic demand during exercise, and IC reflects
lung hyperinflation. Specifically concerning MVV, although
previous data indicated that the diaphragm has limited con-
tribution to the generation of maximal levels of ventilation in
patients with severe COPD,9 in this study we observed a pos-
itive correlation between MVV and respiratory muscle force
(Table 2). Furthermore, there is evidence that MVV may be
responsive to general exercise training programs in COPD
patients,10 unlike what is commonly observed concerning
the FEV1. The present study also showed significant correla-
tion between MVV and 6MWT, as previously described.11 It
is also known that the 6MWT is responsive to exercise train-
ing12 and that there is good correlation between 6MWT and
time spent actively in daily life.13 Therefore, the fact that
MVV is more responsive to exercise training suggests that
this outcome has better predictive value to detect improve-
ments in physical activity in daily life after pulmonary reha-
bilitation programs than the FEV1. Therefore, we suggest
that MVV should be incorporated to the routine of assessment
in pulmonary rehabilitation programs, as well as it should be
included in the methodology of studies concerning the influ-
ence of lung function impairment in the functional status of
patients with COPD.
Current literature concerning the relationship between
FEV1 and the level of physical activity in daily life assessed
by motion sensors is controversial, varying from weak and
not statistically significant to strong and statisticallysignificant correlations.13e17 Differences observed between
the present findings and other studies with relatively
conflicting results 14,15,17 are possibly due to the differ-
ences in the populations’ characteristics and differences
in the tools used for the objective assessment of daily phys-
ical activity. However, it has been previously suggested that
the GOLD stages do not properly differentiate which COPD
patients are active or inactive in daily life, in contrast to
a multi-factorial severity index capable of taking into
account the disease’s systemic characteristics, the BODE
index.18 In the present study, MVV correlated better than
the FEV1 with 6MWT and BMI, which are also components
of the BODE index. This reinforces the message that MVV
better reflects the disease severity as a whole, including
physical inactivity and functional limitation. It is important
to underline, however, that this study was performed with
a sample characterized (by chance) by normal BMI as
a group. Therefore care must be taken when generalizing
these findings to patients with very low or very high BMI.
In conclusion, MVV is a better correlate of the level of
physical activity in daily life, functional exercise capacity
and respiratory muscle force than FEV1 and IC in patients
with COPD. Different stages of disease severity classified
according to the FEV1-based GOLD do not present differ-
ences regarding daily physical activity. This shows that
the reduction in physical activity in daily life in patients
with COPD does not depend on the disease severity deter-
mined solely based on the FEV1. Therefore, the present
study reinforces the idea that although FEV1 might be an
important outcome in order to indicate the severity of
airflow limitation in COPD, it should not be used by itself
as an indication of disease severity in a broader sense.
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